GSK to buy liver disease drug from Boston Pharmaceuticals for up to $2 billion
GSK is set to acquire efimosfermin, a promising liver disease drug, from Boston Pharmaceuticals for a potential $2 billion. The deal includes an upfront payment of $1.2 billion and milestone payments. Efimosfermin, targeting steatotic liver disease and MASH, is expected to launch in 2029, with (...)
Site référencé: The Economic Times
The Economic Times
ETMarkets PMS Talk | Auto Components, Textiles, REITs : Where green portfolio sees dividend-driven value, says Sreeram Ramdas
14/05/2025
Latin America mourns world's 'poorest president' Mujica, dead at 89
14/05/2025
New lifetime high on cards for Nifty ? Deven Choksey’s market outlook
14/05/2025
Q4 results today : Eicher Motor, Tata Power among 126 companies to announce earnings on Wednesday
14/05/2025
Navigating Market Volatility : How STPs can benefit retail investors
14/05/2025
Credit Saison secures $150 million ECB funding from Mizuho
14/05/2025
